Proteomic Screening Applied To Early The Diagnosis Of Chronic Graft-Versus-Host-Disease  by Weissinger, E.M. et al.
Oral Presentations S171mainly severe aplastic anemia. Conditioning regimens included
reduced intensity conditioning regimens (RIC) for about 60% of
the patients of MHH, as well as standard conditioning regimens
(mainly TBI + Cy or Busulfan + Cy). GvHD-prophylaxis was cyclo-
sporine A (CSA) and mycophenolate (MMF) or CSA metothrexate
(MTX), as appropriate. In addition, about 80% percent of the pa-
tients received ATG (antithymocyte globulin) prior to HSCT.
A peptide pattern of 31 peptides – either absent/decreased (15) or
present/increased (16) – was previously published (Weissinger et al.
2007), a new pattern MS_17 was developed and prospectively evalu-
ated in parallel for the last 2 years. Prospective and blinded evalua-
tion of the patients included in this analysis for early recognition
of patients at risk for aGvHD development revealed the correct clas-
sification of patients developing aGvHD about 7 days prior to the
development of clinical symptoms for aGVHD with a sensitivity
76% and specificity of about 85%. Additional data on the efficacy
of a pilot study for pre-emptive therapy driven by pattern positivity
yielded encouraging results on incidence and severity of aGvHD will
be reported. Based on these data a pre-emptive therapy multicenter
trial, administering steroids upon positivity of the proteomic pattern
has been initiated now in 10 German centers, testing the efficacy of
the pre-emptive therapy on incidence and severity of aGvHD and
a possible benefit on overall survival of the patients.44
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Chronic graft versus host disease (GvHD), or late acute GvHD
play a major role in morbidity, but also mortality of patients post al-
logeneic HSCT. Diagnosis chronic GvHD is based on clinical fea-
tures and biopsies, a non invasive, unbiased laboratory test does
not exist.
We established a proteomic screening test for cGvHD by using
capillary electrophoresis (CE) coupled on line to an ESI-Tof (elec-
trospray-ionization time of flight) mass spectrometer (MS). Screen-
ing urine collected from 20 patients (10 with limited cGvHD, 10
with extensive cGvHD) we established a proteomic pattern allowing
the diagnosis of cGvHD development. The resulting set of polypep-
tide markers (27 differentially excreted peptides) was tested on more
than 227 patients prospectively and blinded for the correct classifica-
tion of cGvHD samples. The majority of the patients included were
transplanted for hematological malignancies (n5 209), 6 for hema-
topoietic failure syndromes. The cGvHD proteomic pattern of 27
peptides was established by using 20 cases and 20 controls, consisting
of patients at least 100 days post-HSCT, with no GvHD in the his-
tory, no infections and without relapse at the time of sampling. Apro-
teomic pattern differentiating chronic from acute GvHD was
developed, since the initial pattern did cross react with aGvHD pa-
tients.Prospective and blinded evaluation of the patients revealed
the correct classification of patients developing cGvHD with a
sensitivity of 85% and specificity of 95%. Interestingly, urine from
patients developing GvHD post DLI did react with the cGvHD-
pattern and is predictive for GvHD developing post-DLI (about 2
weeks prior to DLI-GvHD development When the aGvHD-specific
proteomic pattern was applied to the screening of patients with DLI
in order to predict GvHD, only GvHD of the intestine reacted sig-
nificantly with the aGvHD pattern. Further evaluations of the
cGvHD patterns specific for particular organ manifestations are cur-
rently ongoing.45
GRAFT-VERSUS-LEUKEMIA ANTIGEN CML66 ELICITS COORDINATED B
AND T CELL IMMUNITY AFTER DONOR LYMPHOCYTE INFUSION
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Donor lymphocyte infusion (DLI) is a highly effective treatment
for relapsed chronic myeloid leukemia (CML) after allogeneic hema-
topoietic stem cell transplantation (HSCT), in which 70-80% pa-tients achieve curative responses. Despite its clinical efficacy, the
mechanism by which DLI achieves anti-tumor immunity remains
incompletely understood. CML66 is a CML-associated antigen
that is preferentially expressed in myeloid progenitor cells. CML66
elicited a potent antibody response in a patient with CML who
achieved complete molecular remission following CD4 + DLI in
the absence of graft-versus-host disease. Since CD4 + T cell re-
sponses often generate both antigen-specific antibody and CD8 + T
cell responses, we queried whether anti-CML66 antibodies were
associated with the development of cytolytic T cell immunity against
the same protein. CML66-reactive T cell clones were detected and
found to be directed against a naturally processed and presented
HLA-B*4403-restricted epitope (HDVDALLW). This T cell epi-
tope (at residues 459-467) is positioned in a different region of the
protein compared to the B cell epitope (at residues 198-217: GFYV-
SLEWVTISKKNQDNK). Neither antibody nor T cell responses to
CML66 were detectable in peripheral blood prior to DLI, by ELISA
or ELISpot assays, respectively. However, starting as early as one
month after DLI, CD8 + T cells and then high-titer plasma antibody
to CML66 were readily detected in peripheral blood, in close tempo-
ral correlation with disease remission. Examination of marrow by
ELISpot 1 month after DLI revealed a 10 fold increased frequency
of CML66-reactive CD8 + T cells compared to peripheral blood.
The CML66-reactive T cell clone could be also detected at low levels
in vivo in patient marrow prior to DLI by ELISpot and nested PCR,
in association with progressive leukemic relapse, but not in peripheral
blood pre-DLI, nor in peripheral blood of the stem cell donor. These
results suggest that marrow is a reservoir of donor T cells primed
against patient leukemia following HSCT. Infusion of CD4+ donor
T cells appears to result in the rapid expansion of pre-existing mar-
row-resident leukemia-specific CD8 + T cells, followed by a cascade
of antigen-specific immune responses detectable in the periphery.
Our detailed analysis of this single antigen demonstrates that both
B and T cell immunity contribute to effective tumor immunity that
is directed at least in part to nonpolymorphic overexpressed leukemia
antigens.46
IN CML PATIENTS, RESIDUAL DISEASE IN PRIMITIVE STEM/PROGENITOR
CELLS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IS
HIGHER THAN AFTER TREATMENT WITH TYROSINE KINASE INHIBITORS
ALONE, BUT IS STILL AMENABLE TO GVL EFFECTS
Yong, A.S.M., Keyvanfar, K., Eniafe, R., Savani, B.N., Rezvani, K.,
Shenoy, A., Koklanaris, E.K., Musse, L., Donohue, T., Le, Q.,
Goldman, J.M., Barrett, A.J. National Heart, Lung and Blood Institute,
National Institutes of Health, Bethesda, MD
Although tyrosine kinase inhibitors (TKI) have replaced allogeneic
stem cell transplantation (SCT) as first-line therapy for chronic my-
eloid leukemia (CML), TKIs do not eradicate all CML cells. Simi-
larly, although SCT cures CML patients, minimal residual disease
(MRD) not fulfilling criteria for molecular relapse is also found
post-SCT. We compared the level of BCR-ABL transcripts in primi-
tive hematopoietic cells from patients who were treated with T-
depleted SCT with scheduled T-cell addback from D + 45 to
D + 100 post-SCT (n5 38) with levels in those taking TKIs
(n5 5). CD34+ cells were isolated from post-SCT leukaphereses at
D + 120 (n5 13), peripheral blood (PB) from D + 60 – 66 months
(n5 19), bone marrow aspirates from patients on long-term follow-
up (4-12 years) (n5 17), or 15 – 18 months post-TKI treatment alone
(n5 5); serial post-SCT samples were available in 12 patients. Hema-
topoietic stem cells (HSC, CD34 + CD38-Lin-CD90+), common
myeloid progenitors (CMP, CD34 + CD38 + Lin- IL3Ra + C-
D45RA-) and granulocyte-macrophage progenitors (GMP,
CD34 + CD38 + Lin- IL3Ra + CD45RA+) were flow-sorted, and
BCR-ABL expression measured using quantitative PCR with the sen-
sitivity to detect one BCR-ABL-positive cell in 106 normal cells. Of
twenty patients with PB MRD-negativity (n5 19 post-SCT, n5 1
post-TKI), an 11-year post-SCT patient had detectable BCR-ABL
transcripts in CMPs, and subsequently fulfilled criteria for molecular
relapse. Among PB MRD-positive patients, 3/19 (16%) post-SCT
and 2/3 (67%) post-TKI did not have detectable BCR-ABL tran-
scripts in HSC, CMP or GMP populations. In 16/19 (84%) PB
MRD-positive post-SCT patients BCR-ABL transcripts were de-
tected in at least one CD34+ subpopulation, with the highest levels
